Literature DB >> 32196812

Functional characterization of four ATP-binding cassette transporter A3 gene (ABCA3) variants.

June Y Hu1, Ping Yang1, Daniel J Wegner1, Hillary B Heins1, Cliff J Luke1, Fuhai Li1,2, Frances V White3, Gary A Silverman1, F Sessions Cole1, Jennifer A Wambach1.   

Abstract

ABCA3 transports phospholipids across lamellar body membranes in pulmonary alveolar type II cells and is required for surfactant assembly. Rare, biallelic, pathogenic ABCA3 variants result in lethal neonatal respiratory distress syndrome and childhood interstitial lung disease. Qualitative functional characterization of ABCA3 missense variants suggests two pathogenic classes: disrupted intracellular trafficking (type I mutant) or impaired ATPase-mediated phospholipid transport into the lamellar bodies (type II mutant). We qualitatively compared wild-type (WT-ABCA3) with four uncharacterized ABCA3 variants (c.418A>C;p.Asn140His, c.3609_3611delCTT;p.Phe1203del, c.3784A>G;p.Ser1262Gly, and c.4195G>A;p.Val1399Met) in A549 cells using protein processing, colocalization with intracellular organelles, lamellar body ultrastructure, and ATPase activity. We quantitatively measured lamellar body-like vesicle diameter and intracellular ABCA3 trafficking using fluorescence-based colocalization. Three ABCA3 variants (p.Asn140His, p.Ser1262Gly, and p.Val1399Met) were processed and trafficked normally and demonstrated well-organized lamellar body-like vesicles, but had reduced ATPase activity consistent with type II mutants. P.Phe1203del was processed normally, had reduced ATPase activity, and well-organized lamellar body-like vesicles, but quantitatively colocalized with both endoplasmic reticulum and lysosomal markers, an intermediate phenotype suggesting disruption of both intracellular trafficking and phospholipid transport. All ABCA3 mutants demonstrated mean vesicle diameters smaller than WT-ABCA3. Qualitative and quantitative functional characterization of ABCA3 variants informs mechanisms of pathogenicity.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  ABCA3; childhood interstitial lung disease (chILD); lamellar bodies; respiratory distress syndrome (RDS); surfactant

Year:  2020        PMID: 32196812      PMCID: PMC7292786          DOI: 10.1002/humu.24014

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  39 in total

1.  Molecular and cellular characteristics of ABCA3 mutations associated with diffuse parenchymal lung diseases in children.

Authors:  Florence Flamein; Laure Riffault; Céline Muselet-Charlier; Julie Pernelle; Delphine Feldmann; Laurence Jonard; Anne-Marie Durand-Schneider; Aurore Coulomb; Michèle Maurice; Lawrence M Nogee; Nobuya Inagaki; Serge Amselem; Jean Christophe Dubus; Virginie Rigourd; François Brémont; Christophe Marguet; Jacques Brouard; Jacques de Blic; Annick Clement; Ralph Epaud; Loïc Guillot
Journal:  Hum Mol Genet       Date:  2011-11-07       Impact factor: 6.150

2.  Identification of LBM180, a lamellar body limiting membrane protein of alveolar type II cells, as the ABC transporter protein ABCA3.

Authors:  Surafel Mulugeta; Joseph M Gray; Kathleen L Notarfrancesco; Linda W Gonzales; Michael Koval; Sheldon I Feinstein; Philip L Ballard; Aron B Fisher; Henry Shuman
Journal:  J Biol Chem       Date:  2002-04-08       Impact factor: 5.157

3.  An SFTPC BRICHOS mutant links epithelial ER stress and spontaneous lung fibrosis.

Authors:  Jeremy Katzen; Brandie D Wagner; Alessandro Venosa; Meghan Kopp; Yaniv Tomer; Scott J Russo; Alvis C Headen; Maria C Basil; James M Stark; Surafel Mulugeta; Robin R Deterding; Michael F Beers
Journal:  JCI Insight       Date:  2019-03-21

4.  Aberrant catalytic cycle and impaired lipid transport into intracellular vesicles in ABCA3 mutants associated with nonfatal pediatric interstitial lung disease.

Authors:  Yoshihiro Matsumura; Nobuhiro Ban; Nobuya Inagaki
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-08-01       Impact factor: 5.464

5.  Predicting functional effect of human missense mutations using PolyPhen-2.

Authors:  Ivan Adzhubei; Daniel M Jordan; Shamil R Sunyaev
Journal:  Curr Protoc Hum Genet       Date:  2013-01

6.  Clinical, radiological and pathological features of ABCA3 mutations in children.

Authors:  M L Doan; R P Guillerman; M K Dishop; L M Nogee; C Langston; G B Mallory; M M Sockrider; L L Fan
Journal:  Thorax       Date:  2007-11-16       Impact factor: 9.139

7.  Functional Characterization of ATP-Binding Cassette Transporter A3 Mutations from Infants with Respiratory Distress Syndrome.

Authors:  Jennifer A Wambach; Ping Yang; Daniel J Wegner; Hillary B Heins; Lyudmila N Kaliberova; Sergey A Kaliberov; David T Curiel; Frances V White; Aaron Hamvas; Brian P Hackett; F Sessions Cole
Journal:  Am J Respir Cell Mol Biol       Date:  2016-11       Impact factor: 6.914

8.  Potentiation of ABCA3 lipid transport function by ivacaftor and genistein.

Authors:  Susanna Kinting; Yang Li; Maria Forstner; Florent Delhommel; Michael Sattler; Matthias Griese
Journal:  J Cell Mol Med       Date:  2019-06-18       Impact factor: 5.310

9.  Analysis of the Proteolytic Processing of ABCA3: Identification of Cleavage Site and Involved Proteases.

Authors:  Nicole Hofmann; Dmitry Galetskiy; Daniela Rauch; Thomas Wittmann; Andreas Marquardt; Matthias Griese; Ralf Zarbock
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

Review 10.  CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis.

Authors:  Miquéias Lopes-Pacheco
Journal:  Front Pharmacol       Date:  2016-09-05       Impact factor: 5.810

View more
  7 in total

1.  Strategies to gain novel Alzheimer's disease diagnostics and therapeutics using modulators of ABCA transporters.

Authors:  Jens Pahnke; Pablo Bascuñana; Mirjam Brackhan; Katja Stefan; Vigneshwaran Namasivayam; Radosveta Koldamova; Jingyun Wu; Luisa Möhle; Sven Marcel Stefan
Journal:  Free Neuropathol       Date:  2021-12-13

2.  Biologic characterization of ABCA3 variants in lung tissue from infants and children with ABCA3 deficiency.

Authors:  Kathryn K Xu; Daniel J Wegner; Lucille C Geurts; Hillary B Heins; Ping Yang; Aaron Hamvas; Pirooz Eghtesady; Stuart C Sweet; F Sessions Cole; Jennifer A Wambach
Journal:  Pediatr Pulmonol       Date:  2022-03-17

3.  Diagnostic Challenges in Neonatal Respiratory Distress-Congenital Surfactant Metabolism Dysfunction Caused by ABCA3 Mutation.

Authors:  Justyna Rogulska; Katarzyna Wróblewska-Seniuk; Robert Śmigiel; Jarosław Szydłowski; Tomasz Szczapa
Journal:  Diagnostics (Basel)       Date:  2022-04-26

4.  Functional Genomics of ABCA3 Variants.

Authors:  Jennifer A Wambach; Ping Yang; Daniel J Wegner; Hillary B Heins; Cliff Luke; Fuhai Li; Frances V White; F Sessions Cole
Journal:  Am J Respir Cell Mol Biol       Date:  2020-10       Impact factor: 6.914

Review 5.  Gene Therapy Potential for Genetic Disorders of Surfactant Dysfunction.

Authors:  Ashley L Cooney; Jennifer A Wambach; Patrick L Sinn; Paul B McCray
Journal:  Front Genome Ed       Date:  2022-01-14

6.  Rare-variant collapsing analyses identified risk genes for neonatal acute respiratory distress syndrome.

Authors:  Huiyao Chen; Xiang Chen; Liyuan Hu; Chang Ye; Jiantao Zhang; Guoqiang Cheng; Lin Yang; Yulan Lu; Xinran Dong; Wenhao Zhou
Journal:  Comput Struct Biotechnol J       Date:  2022-09-01       Impact factor: 6.155

7.  The common ABCA3E292V variant disrupts AT2 cell quality control and increases susceptibility to lung injury and aberrant remodeling.

Authors:  Yaniv Tomer; Jennifer Wambach; Lars Knudsen; Ming Zhao; Luis R Rodriguez; Aditi Murthy; Frances V White; Alessandro Venosa; Jeremy Katzen; Matthias Ochs; Aaron Hamvas; Michael F Beers; Surafel Mulugeta
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-06-16       Impact factor: 6.011

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.